Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X
Analysis

September’s top stories: Novartis Afinitor Phase III trial, Boehringer COPD study

Novartis reported positive Phase III trial results of pancreatic cancer drug Afinitor, Boehringer reported positive data from Phase III trials of COPD combination drug and Exelixis' Phase III prostate cancer trial of cabozantinib fails to meet primary endpoint. Drugdevelopment-technology.com wraps up key headlines from September 2014.

Go Top